European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business ...

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

“特别声明：以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布，本平台仅 ...

Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 ...

欧盟反垄断当局将于2023年12月6日前就诺和控股(Novo Holdings)拟议收购Catalent一事做出决定。作为诺和诺德公司(Novo Nordisk)的控股股东，诺和控股于10月31日寻求欧盟批准该交易。 Catalent是一家在纽约证券交易所上市的合同药品制造商，股票代码为NYSE:CTLT，是此次收购的核心。负责反垄断事务的欧盟委员会可以选择有条件地批准交易、无条件地批准交易，或者 ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

周二，合同药品制造商Catalent（纽交所代码：CTLT）公布的第一季度收入未能达到华尔街预期。该公司目前正在被诺和诺德公司旗下的Novo Holdings收购，本季度出现了意外亏损。 Catalent以提供注射器和注射笔的无菌填充和包装服务而闻名，是诺和诺德公司（纽交所代码：NVO）Wegovy减肥药的主要供应商。今年2月，持有诺和诺德公司控股权的Novo Holdings启动了对Catale ...